Business, energy, technology, markets and global industry news from Business News Today

amivantamab

PharmaDeviceNews amivantamab
Johnson & Johnson’s PAPILLON trial reported 34.3-month median survival with first-line RYBREVANT plus chemotherapy, while extensive treatment crossover complicated the final overall-survival analysis. Representative image.
Features & Analysis

Johnson & Johnson says RYBREVANT delivered the longest reported survival in EGFR exon 20 lung cancer. Why was p=0.307?

Johnson & Johnson’s final PAPILLON analysis found median overall survival of 34.3 months with first-line RYBREVANT plus chemotherapy versus 27.9 months with chemotherapy, but the protocol-specified comparison was not statistically significant. With 76% of eligible chemotherapy patients later receiving amivantamab, the trial has become a case study in how effective crossover can obscure overall-survival differences.

Read More
Representative image: An oncologist reviews lung scan and precision medicine data, reflecting how Rybrevant plus Lazcluze could reshape first-line treatment expectations for atypical EGFR-mutated non-small cell lung cancer.
Pharma & Biotech

Is atypical EGFR-mutated NSCLC becoming Johnson & Johnson’s next precision oncology battleground?

Atypical EGFR lung cancer lacks clear first-line answers. Rybrevant plus Lazcluze may change that, but trial size still matters.

Read More
Representative image of a bispecific antibody targeting a colorectal tumor, illustrating the EGFR and MET pathway inhibition explored in the OrigAMI-1 trial of amivantamab in metastatic colorectal cancer.
Pharma & Biotech

J&J’s amivantamab shows strong first-line response in metastatic colorectal cancer

Johnson & Johnson (J&J) has reported updated results from its Phase 1b/2 OrigAMI-1 trial evaluating amivantamab-vmjw in combination with chemotherapy for patients with RAS/BRAF wild-type metastatic colorectal cancer. The bispecific antibody, which targets epidermal growth factor receptor (EGFR) and MET, achieved confirmed response rates of 73 percent in the first-line setting and 44 percent in

Read More
Representative image: An oncologist discusses subcutaneous lung cancer treatment with a patient. The recent FDA approval of RYBREVANT FASPRO for EGFR-mutated NSCLC highlights a shift toward faster, chemotherapy-free options.
Pharma & Biotech

FDA clears subcutaneous RYBREVANT FASPRO for first-line EGFR+ NSCLC: What this changes for patients and providers

The U.S. Food and Drug Administration has approved Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), the first subcutaneous version of its bispecific EGFR-MET antibody therapy, for patients with EGFR-mutated non-small cell lung cancer (NSCLC). The approval spans all current RYBREVANT indications and is based on the Phase 3 PALOMA-3 study, which demonstrated comparable pharmacokinetics

Read More